

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL SEARCHING AUTHORITY

To:

see form PCT/ISA/220

PCT

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**  
**(PCT Rule 43bis.1)**

Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet)
---

Applicant's or agent's file reference see form PCT/ISA/220	<b>FOR FURTHER ACTION</b> See paragraph 2 below
---	--

International application No. PCT/US2007/017123	International filing date (day/month/year) 31.07.2007	Priority date (day/month/year) 03.08.2006
--	--	--

International Patent Classification (IPC) or both national classification and IPC INV. G06F19/00 A61M5/172
---

Applicant SMITHS MEDICAL MD, INC.
--------------------------------------

**1. This opinion contains indications relating to the following items:**

- Box No. I Basis of the opinion
- Box No. II Priority
- Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- Box No. VI Certain documents cited
- Box No. VII Certain defects in the international application
- Box No. VIII Certain observations on the international application

**2. FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

**3. For further details, see notes to Form PCT/ISA/220.**

Name and mailing address of the ISA:	Date of completion of this opinion
--------------------------------------	---------------------------------------



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Date of completion of  
this opinion

see form  
PCT/ISA/210

Authorized Officer

Ceccarelli, David

Telephone No. +49 89 2399-2653



**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.  
PCT/US2007/017123

---

**Box No. I Basis of the opinion**

---

1. With regard to the **language**, this opinion has been established on the basis of:  
 the international application in the language in which it was filed  
 a translation of the international application into , which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1 (b)).
2.  This opinion has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43bis.1(a))
3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
  - a. type of material:  
 a sequence listing  
 table(s) related to the sequence listing
  - b. format of material:  
 on paper  
 in electronic form
  - c. time of filing/furnishing:  
 contained in the international application as filed.  
 filed together with the international application in electronic form.  
 furnished subsequently to this Authority for the purposes of search.
4.  In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
5. Additional comments:

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.  
PCT/US2007/017123

---

**Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or  
industrial applicability; citations and explanations supporting such statement**

---

1. Statement

Novelty (N)	Yes: Claims	<u>2-10-12-21</u>
	No: Claims	<u>1,11</u>
Inventive step (IS)	Yes: Claims	
	No: Claims	<u>1-21</u>
Industrial applicability (IA)	Yes: Claims	<u>1-21</u>
	No: Claims	

2. Citations and explanations

**see separate sheet**

---

**Box No. VII Certain defects in the international application**

---

The following defects in the form or contents of the international application have been noted:

**see separate sheet**

**Re Item V**

**Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Independent claims 1 and 11 are clearly not novel (Article 33(2) PCT) over the disclosure of document US2006/0079768 (D1) for example. Said document D1 shows an apparatus and a corresponding method for indicating a current condition of a medical infusion pump (see display 208 in figures 4A and 4B, for example) comprising a memory configured to store two or more colour codes (see paragraphs 66 and 67 in general), a monitor (display 208), a programmable circuit (see paragraph 53) programmed to generate a graphical user interface displaying a colour upon detection of a condition (see paragraph 67).
2. Claims 2-10 and 12-21 are at least not inventive (Article 33(3) PCT) when document D1 is considered as closest prior art. In general, the idea of associating a colour to a detected condition of an infusion pump is known at least from document D1. Where on the monitor and under which form to display the colour, and under which condition the colour should be displayed is a clear matter of design for the skilled man in the light of the disclosure of paragraphs 66 and 67 of document D1.

**Re Item VII**

**Certain defects in the international application**

Document D1 is not cited in the description (Rule 5.1(a)(ii) PCT).

The independent claims are not drafted in the two-part form (Rule 6.3(b) PCT).

The claims do not contain any reference signs to the figures (Rule 6.2(b) PCT).